VIRALEZE™ antiviral nasal spray launched in ADMENTA Italia Group pharmacies in Italy

MELBOURNE, Australia, Oct. 8, 2021

VIRALEZE™ is expected to be available to Italian consumers this quarter through ADMENTA's extensive LloydsFarmacia chain, which comprises 260 retail pharmacies, including 13 parapharmacies and 50 franchising pharmacies, as well as LloydsFarmacia's online platform. 

VIRALEZE™ is a broad-spectrum antiviral nasal spray, applied in the nose to provide a physical barrier – between viruses and the nasal mucous membrane – which traps and irreversibly inactivates viruses, including SARS-CoV-2. Its antiviral agent, SPL7013, has been shown in laboratory studies to have potent antiviral and virucidal activity in multiple respiratory viruses, including multiple variants of SARS-CoV-2, where it has been shown to inactivate >99.9% of the highly infectious Delta variant.

ADMENTA employs 1,400 people in Italy across its wholesale and retail operations, supplying more than 2,500 pharmacies, parapharmacies, drug stores and hospitals. 

ADMENTA is also the Italian holding company of McKesson Europe. The US-based McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology.

Vincenzo Masci, Marketing and Procurement Director of ADMENTA-LloydsFarmacia, said: "We are delighted to have partnered with Starpharma for VIRALEZE™ antiviral nasal spray in Italy. VIRALEZE™ will be an excellent addition to both our retail and distribution sectors as we head towards winter." 

Dr Jackie Fairley, CEO of Starpharma, said: "We are very pleased to have partnered with ADMENTA in Italy and we look forward to having VIRALEZE™ available soon to Italian consumers, through pharmacies as well as through the leading LloydsFarmacia online platform."